CD73 activity and outcome of advanced melanoma patients treated with nivolumab

      Background: Nivolumab is an anti-PD1 agent used to treat patients with advanced melanoma. Here we report the CD73 enzymatic activity in melanoma patients receiving nivolumab. CD73 is an enzyme involved in the generation of adenosine, a metabolic mediator that potently suppresses anti-tumor T-cell responses.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect